Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Piperazines/administration & dosage"'
Autor:
Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman
Publikováno v:
Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c34416fb3adf2a299c05113cf960a2c
https://doi.org/10.1016/s1470-2045(20)30324-7
https://doi.org/10.1016/s1470-2045(20)30324-7
Autor:
Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin
Publikováno v:
Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c882e2c41b9625dab34c1f829ff27
https://doi.org/10.1080/15384047.2019.1685291
https://doi.org/10.1080/15384047.2019.1685291
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer
Autor:
Sheryl Roberts, Susanne Kossatz, Christian Brand, M. Jason de la Cruz, Willem J. M. Mulder, Junior Gonzales, Thomas Reiner, Giacomo Pirovano, Patrick L. Donabedian, Carlos Pérez-Medina
Publikováno v:
Bioconjugate Chemistry, 29(11), 3776-3782. American Chemical Society
Bioconjugate chemistry, 29(11), 3776-3782. American Chemical Society
Bioconjugate chemistry, 29(11), 3776-3782. American Chemical Society
The preclinical potential of many diagnostic and therapeutic small molecules is limited by their rapid washout kinetics and consequently modest pharmacological performances. In several cases, these could be improved by loading the small molecules int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a32309149150e80d69849105b78ad1
https://europepmc.org/articles/PMC6548450/
https://europepmc.org/articles/PMC6548450/
Publikováno v:
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Introduction: Recently, new targeted agents have been developed, which can prolong the effect of endocrine treatment (ET) by targeting resistance pathways in HR+/HER2− advanced breast cancer. This review examines available studies of everolimus, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0942932052480a705d1f354fa46e9
https://pubmed.ncbi.nlm.nih.gov/30375908
https://pubmed.ncbi.nlm.nih.gov/30375908
Autor:
Chalandon, Yves, Thomas, Xavier, Hayette, Sandrine, Cayuela, Jean-Michel, Abbal, Claire, Huguet, Françoise, Raffoux, Emmanuel, Leguay, Thibaut, Rousselot, Philippe, Lepretre, Stéphane, Escoffre-Barbe, Martine, Maury, Sébastien, Berthon, Céline, Tavernier, Emmanuelle, Lambert, Jean-François, Lafage-Pochitaloff, Marina, Lhéritier, Véronique, Chevret, Sylvie, Ifrah, Norbert, Dombret, Hervé, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Publikováno v:
Blood, Vol. 125, No 24 (2015) pp. 3711-3719
In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) in 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ff7b8fa7c747ce8aaa642d7f259a20
https://doi.org/10.1182/blood-2015-02-627935
https://doi.org/10.1182/blood-2015-02-627935
Autor:
Elaine Kilgour, Marie Cullberg, Jean-Charles Soria, Michael F. Berger, David Ferry, Fabrice Andre, A. Nigel Brooks, Ronglai Shen, Paul K. Paik, Claire Rooney, Neil R. Smith, Donal Landers, Alastair Mathewson, Paul Frewer
Publikováno v:
Paik, P K, Shen, R, Berger, M F, Ferry, D, Soria, J-C, Mathewson, A, Rooney, C, Smith, N R, Cullberg, M, Kilgour, E, Landers, D, Frewer, P, Brooks, N & André, F 2017, ' A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, no. 18, pp. 5366-5373 . https://doi.org/10.1158/1078-0432.CCR-17-0645
Purpose: Squamous cell lung cancers (SQCLC) account for 25% of all NSCLCs, yet the prognosis of these patients is poor and treatment options are limited. Amplified FGFR1 is one of the most common oncogenic events in SQCLCs, occurring in approximately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990f2a483a46e22776bff83e60c537f8
https://research.manchester.ac.uk/en/publications/3279fad9-f754-4e8a-b3e0-f835a5a0b263
https://research.manchester.ac.uk/en/publications/3279fad9-f754-4e8a-b3e0-f835a5a0b263
Autor:
Irina Konourina, Robyn J. Barst, D. Dunbar Ivy, Tomás Pulido, Maurice Beghetti, Min Zhang, Gary Layton
Publikováno v:
Circulation, Vol. 129, No 19 (2014) pp. 1914-23
Background— The double-blind, placebo-controlled Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study assessed sildenafil in pediatric patients with pulmonary arterial hypertension; impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6afb5d82676502848b724d3c2d915cd1
https://doi.org/10.1161/circulationaha.113.005698
https://doi.org/10.1161/circulationaha.113.005698
Autor:
Alia Bana, Monique L. Smith, Amynah A. Pradhan, Christopher J. Evans, Ana Vicente-Sánchez, Julie Perroy, Laura Segura, Wendy Walwyn, Brigitte L. Kieffer
Publikováno v:
Journal of Neuroscience
Journal of Neuroscience, Society for Neuroscience, 2016, 36 (12), pp.3541--51. ⟨10.1523/JNEUROSCI.4124-15.2016⟩
The Journal of neuroscience : the official journal of the Society for Neuroscience, vol 36, iss 12
Journal of Neuroscience, Society for Neuroscience, 2016, 36 (12), pp.3541--51. ⟨10.1523/JNEUROSCI.4124-15.2016⟩
The Journal of neuroscience : the official journal of the Society for Neuroscience, vol 36, iss 12
Ligand-specific recruitment of arrestins facilitates functional selectivity of G-protein-coupled receptor signaling. Here, we describe agonist-selective recruitment of different arrestin isoforms to the delta opioid receptor in mice. A high-internali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f8503f8710cabfa08e5bd461a79b54
https://hal.archives-ouvertes.fr/hal-01936373
https://hal.archives-ouvertes.fr/hal-01936373
Autor:
Marie-Christiane Vekemans, Martine Escoffre, Norbert Ifrah, Hervé Dombret, Delphine Rea, Aline Tanguy-Schmidt, Xavier Thomas, Sandrine Hayette, Philippe Rousselot, André Delannoy, Yves Chalandon, Jean-Paul Vernant, Jean-Yves Cahn, Françoise Huguet, Jean-Michel Cayuela
Publikováno v:
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2013, 19 (1), pp.150-5. ⟨10.1016/j.bbmt.2012.08.021⟩
Biology of Blood and Marrow Transplantation, Vol. 19, No 1 (2013) pp. 150-5
Biology of Blood and Marrow Transplantation, Elsevier, 2013, 19 (1), pp.150-5. ⟨10.1016/j.bbmt.2012.08.021⟩
Biology of Blood and Marrow Transplantation, Vol. 19, No 1 (2013) pp. 150-5
International audience; We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7e5f3f21afc7c2694bd34f9f739d6a
https://hal.archives-ouvertes.fr/hal-00849684
https://hal.archives-ouvertes.fr/hal-00849684
Autor:
Elizabeth Macintyre, Francis Witz, Eric Delabesse, Arnaud Pigneux, Martine Escoffre, Philippe Rousselot, Véronique Lhéritier, Jean-Michel Cayuela, Yves Chalandon, M C Vekemans, Delphine Rea, Oumedaly Reman, Norbert Ifrah, Xavier Thomas, Jean-Paul Vernant, Sébastien Maury, Adrienne de Labarthe, Francoise Huguet-Rigal, Hervé Dombret, Agnes Buzyn
Publikováno v:
Blood, Vol. 109, No 4 (2007) pp. 1408-13
The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d010f8c8c434d034f5ccc9840aff543
https://archive-ouverte.unige.ch/unige:26015
https://archive-ouverte.unige.ch/unige:26015